Biocon Limited
20th KM Hosur Road
Electronics City
Bangalore 560 100, India
T 91 80 2808 2808
F 91 80 2852 3423
CIN : L24234KA1978PLC003417

www.biocon.com

Date of submission: November 30, 2018

To The Secretary BSE Limited Department of Corporate Services Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001 Scrip Code - 532523	To The Secretary National Stock Exchange of India Limited Exchange Plaza, Bandra Kurla Complex Mumbai – 400 050 Scrip Code- BIOCON

Dear Sir/Madam,

Sub: Biosimilar Pegfilgrastim Co-Developed by Biocon Receives Approval in EU

Ref: Regulations 30 of SEBI Listing Obligations and Disclosure Requirements (LODR) Regulations, 2015.

Pursuant to Regulation 30 of the SEBI LODR Regulations, 2015, please find below the "Company Statement" on the subject matter.

"Fulphila®, a biosimilar Pegfilgrastim jointly developed by Biocon and Mylan, has been approved in EU. The European Commission has granted Marketing Authorization for Fulphila® to our partner Mylan.

The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) had issued a positive opinion recommending approval of Fulphila® as a biosimilar to Amgen's Neulasta®, which is indicated for the reduction in the duration of neutropenia and the incidence of febrile neutropenia in adult patients treated with cytotoxic chemotherapy for malignancy, in September 2018.

Biosimilar Pegfilgrastim treatment can be used to stimulate bone marrow to produce more neutrophils to fight infection in patients undergoing chemotherapy." - *Company Spokesperson*

We request you to kindly take this to your records as per the requirement of LODR and oblige.

Thanking You,
Yours faithfully
For Biocon Limited

Siddharth Mittal
Chief Financial Officer